318 related articles for article (PubMed ID: 32987138)
1. NK cells-directed therapies target circulating tumor cells and metastasis.
Dianat-Moghadam H; Mahari A; Heidarifard M; Parnianfard N; Pourmousavi-Kh L; Rahbarghazi R; Amoozgar Z
Cancer Lett; 2021 Jan; 497():41-53. PubMed ID: 32987138
[TBL] [Abstract][Full Text] [Related]
2. Circulating and disseminated tumour cells - mechanisms of immune surveillance and escape.
Mohme M; Riethdorf S; Pantel K
Nat Rev Clin Oncol; 2017 Mar; 14(3):155-167. PubMed ID: 27644321
[TBL] [Abstract][Full Text] [Related]
3. Control of Metastasis by NK Cells.
López-Soto A; Gonzalez S; Smyth MJ; Galluzzi L
Cancer Cell; 2017 Aug; 32(2):135-154. PubMed ID: 28810142
[TBL] [Abstract][Full Text] [Related]
4. Sweeping lymph node micrometastases off their feet: an engineered model to evaluate natural killer cell mediated therapeutic intervention of circulating tumor cells that disseminate to the lymph nodes.
Chandrasekaran S; McGuire MJ; King MR
Lab Chip; 2014 Jan; 14(1):118-27. PubMed ID: 23934067
[TBL] [Abstract][Full Text] [Related]
5. Jinfukang inhibits lung cancer metastasis by upregulating CX3CL1 to recruit NK cells to kill CTCs.
Que ZJ; Yao JL; Zhou ZY; Yu P; Luo B; Li HG; Liu JX; Xu HX; Tian JH
J Ethnopharmacol; 2021 Jul; 275():114175. PubMed ID: 33933571
[TBL] [Abstract][Full Text] [Related]
6. Mesenchymal Stromal Cells Increase the Natural Killer Resistance of Circulating Tumor Cells via Intercellular Signaling of cGAS-STING-IFNβ-HLA.
Yi Y; Qin G; Yang H; Jia H; Zeng Q; Zheng D; Ye S; Zhang Z; Liu TM; Luo KQ; Deng CX; Xu RH
Adv Sci (Weinh); 2024 Jun; 11(21):e2400888. PubMed ID: 38638003
[TBL] [Abstract][Full Text] [Related]
7. Bench to bedside: NK cells and control of metastasis.
Krasnova Y; Putz EM; Smyth MJ; Souza-Fonseca-Guimaraes F
Clin Immunol; 2017 Apr; 177():50-59. PubMed ID: 26476139
[TBL] [Abstract][Full Text] [Related]
8. Comparative analysis of innate immune system function in metastatic breast, colorectal, and prostate cancer patients with circulating tumor cells.
Santos MF; Mannam VK; Craft BS; Puneky LV; Sheehan NT; Lewis RE; Cruse JM
Exp Mol Pathol; 2014 Jun; 96(3):367-74. PubMed ID: 24731923
[TBL] [Abstract][Full Text] [Related]
9. Targeting natural killer cells in cancer immunotherapy.
Guillerey C; Huntington ND; Smyth MJ
Nat Immunol; 2016 Aug; 17(9):1025-36. PubMed ID: 27540992
[TBL] [Abstract][Full Text] [Related]
10. The biology and clinical potential of circulating tumor cells.
Lozar T; Gersak K; Cemazar M; Kuhar CG; Jesenko T
Radiol Oncol; 2019 May; 53(2):131-147. PubMed ID: 31104002
[TBL] [Abstract][Full Text] [Related]
11. NK cells shape pancreatic and oral tumor microenvironments; role in inhibition of tumor growth and metastasis.
Jewett A; Kos J; Fong Y; Ko MW; Safaei T; Perišić Nanut M; Kaur K
Semin Cancer Biol; 2018 Dec; 53():178-188. PubMed ID: 30081230
[TBL] [Abstract][Full Text] [Related]
12. Circulating tumor cell-blood cell crosstalk: Biology and clinical relevance.
Pereira-Veiga T; Schneegans S; Pantel K; Wikman H
Cell Rep; 2022 Aug; 40(9):111298. PubMed ID: 36044866
[TBL] [Abstract][Full Text] [Related]
13. NK cells to cure cancer.
Di Vito C; Mikulak J; Zaghi E; Pesce S; Marcenaro E; Mavilio D
Semin Immunol; 2019 Feb; 41():101272. PubMed ID: 31085114
[TBL] [Abstract][Full Text] [Related]
14. Editorial: Molecular Strategies Aimed to Boost NK Cell-Based Immunotherapy of Cancer.
Cifaldi L; Di Santo J; Olive D
Front Immunol; 2020; 11():1132. PubMed ID: 32612604
[No Abstract] [Full Text] [Related]
15. Neutrophil: A New Player in Metastatic Cancers.
Wu M; Ma M; Tan Z; Zheng H; Liu X
Front Immunol; 2020; 11():565165. PubMed ID: 33101283
[TBL] [Abstract][Full Text] [Related]
16. Circulating tumor cell as the functional aspect of liquid biopsy to understand the metastatic cascade in solid cancer.
Cortés-Hernández LE; Eslami-S Z; Alix-Panabières C
Mol Aspects Med; 2020 Apr; 72():100816. PubMed ID: 31377345
[TBL] [Abstract][Full Text] [Related]
17. Circulating tumor cells (CTCs) from metastatic breast cancer patients linked to decreased immune function and response to treatment.
Green TL; Cruse JM; Lewis RE; Craft BS
Exp Mol Pathol; 2013 Oct; 95(2):174-9. PubMed ID: 23831428
[TBL] [Abstract][Full Text] [Related]
18. Natural killer group 2D receptor and its ligands in cancer immune escape.
Duan S; Guo W; Xu Z; He Y; Liang C; Mo Y; Wang Y; Xiong F; Guo C; Li Y; Li X; Li G; Zeng Z; Xiong W; Wang F
Mol Cancer; 2019 Feb; 18(1):29. PubMed ID: 30813924
[TBL] [Abstract][Full Text] [Related]
19. Challenges and Recent Advances in NK Cell-Targeted Immunotherapies in Solid Tumors.
Lian G; Mak TS; Yu X; Lan HY
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008589
[TBL] [Abstract][Full Text] [Related]
20. NK Cell Adoptive Immunotherapy of Cancer: Evaluating Recognition Strategies and Overcoming Limitations.
Sanchez CE; Dowlati EP; Geiger AE; Chaudhry K; Tovar MA; Bollard CM; Cruz CRY
Transplant Cell Ther; 2021 Jan; 27(1):21-35. PubMed ID: 33007496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
